therapy chemo combo increase
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Twitter ~ Facebook
Home / Technology News / 2010 / October 2010 / October 11, 2010
TTF therapy, chemo combo 'increase survival for lung cancer patients'
RSS / Print / Comments

Brain cancer

TTF therapy, chemo combo 'increase survival for lung cancer patients'

How genetic changes make some brain cancers more aggressive

Pavin brings in F-16 fighter pilot to motivate US golf team ahead of Ryder Cup

More on Brain cancer

Lung Cancer

TTF therapy, chemo combo 'increase survival for lung cancer patients'

Surveys Highlight Advancing Confidence in Erbitux as Only Targeted Treatment to Increase Survival and Potential for Cure in Head and Neck Cancer

More on Lung Cancer

Technology News

Study to find whether leptin helps type 1 diabetic patients
To determine whether adding the hormone leptin to standard insulin therapy might help rein in the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes, a clinical trial at UT Southwestern Medical Center is being carried out. ANI

Why deaf have 'super vision'
Researchers have found reasons for the enhanced abilities in the remaining senses of deaf people. ANI

Tsunami risk higher than expected in LA, other major cities
A new study has revealed that the risk of destructive tsunamis is in places such as Kingston, Istanbul, and Los Angeles. ANI

TTF therapy, chemo combo 'increase survival for lung cancer patients'

Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumour treating fields (TTF) therapy was added to chemotherapy, as compared to chemotherapy alone.


Washington, Oct 11 : Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumour treating fields (TTF) therapy was added to chemotherapy, as compared to chemotherapy alone.

Physicians delivered TTF Therapy to patients in the study using the NovoTTF-100L-a portable, non-invasive medical device.

The 42 patients had locally advanced and metastatic NSCLC (stage IIIb-IV) and had failed prior treatments with chemotherapy. Patients in the study received TTF Therapy for 12 hours a day in combination with pemetrexed (Alimta; Eli Lilly) until disease progression.

Novocure reported a successful phase III clinical trial of TTF monotherapy in patients with recurrent glioblastoma, an aggressive form of brain cancer.

"We were pleased to report on the results of this multi-center trial of TTF Therapy in a non-brain tumor indication," said Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland.

"We believe this study has shown TTF Therapy to be completely non-toxic and to have the potential to act as a significant adjunct to chemotherapy in the treatment of NSCLC and other solid tumour indications," he added.

Patients treated with TTF Therapy in combination with pemetrexed had a median overall survival time of 13.8 months compared with the 8.3 months reported for pemetrexed alone.

The one-year survival rate for the combination was 57 percent compared with the 30 percent reported for pemetrexed alone.

The adverse event for TTF Therapy was mild to moderate skin irritation at the treatment site.

Results of this phase III trial have been filed with the U.S. Food and Drug Administration (FDA).

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us